I 
119TH CONGRESS 
1ST SESSION 
H. R. 586 
To direct the Secretary of Veterans Affairs to study and report on the 
prevalence of cholangiocarcinoma in veterans who served in the Vietnam 
theater of operations during the Vietnam era, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 21, 2025 
Mr. LALOTA (for himself, Mr. RYAN, Mr. FITZPATRICK, Mr. DAVIS of North 
Carolina, Mr. GOTTHEIMER, and Mr. CISCOMANI) introduced the fol-
lowing bill; which was referred to the Committee on Veterans’ Affairs 
A BILL 
To direct the Secretary of Veterans Affairs to study and 
report on the prevalence of cholangiocarcinoma in vet-
erans who served in the Vietnam theater of operations 
during the Vietnam era, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Vietnam Veterans 
Liver Fluke Cancer Study Act’’. 
VerDate Sep 11 2014 
19:29 Feb 18, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H586.IH
H586
ssavage on LAPJG3WLY3PROD with BILLS
SEC. 
2. 
STUDY 
ON 
THE 
PREVALENCE 
OF 
CHOLANGIOCARCINOMA IN VETERANS WHO 
SERVED IN THE VIETNAM THEATER OF OPER-
ATIONS DURING THE VIETNAM ERA. 
(a) EPIDEMIOLOGICAL STUDY.—Not later than 120 
days after the date of enactment of this Act, the Secretary 
of Veterans Affairs, in consultation with the Director of 
the Centers for Disease Control and Prevention of the De-
partment of Health and Human Services, shall commence 
an 
epidemiological 
study 
on 
the 
prevalence 
of 
cholangiocarcinoma in covered veterans of the Vietnam 
era, using data from the Veterans Affairs Central Cancer 
Registry and the National Program of Cancer Registries. 
The study shall include— 
(1) an identification of the rate of incidence of 
cholangiocarcinoma in covered veterans of the Viet-
nam era and in residents of the United States, from 
the beginning of the Vietnam era to the date of en-
actment of this Act; and 
(2) for each of the groups specified in para-
graph (1), an identification of the percentage of in-
dividuals with cholangiocarcinoma by various demo-
graphic characteristics, including by age, gender, 
race, ethnicity, and the geographic location of the 
patient at the time of diagnosis. 
(b) REPORTS TO CONGRESS.— 
VerDate Sep 11 2014 
19:29 Feb 18, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H586.IH
H586
ssavage on LAPJG3WLY3PROD with BILLS
(1) INITIAL REPORT.—Not later than one year 
after the completion of the study under subsection 
(a), the Secretary shall submit to Congress a report 
containing— 
(A) the results of the study under sub-
section (a); and 
(B) recommendations for administrative or 
legislative actions required to address issues 
identified in the study under subsection (a). 
(2) FOLLOW-UP REPORTS.—The Secretary shall 
periodically submit to the Congress a follow-up re-
ports, as determined by the Secretary, to provide up-
dates to the information included in the initial re-
port under paragraph (1) and information collected 
pursuant to subsection (c). 
(c) 
CONTINUED
TRACKING
OF 
CHOLANGIOCARCINOMA IN COVERED VETERANS OF THE 
VIETNAM ERA.—The Secretary shall track the prevalence 
of cholangiocarcinoma in covered veterans of the Vietnam 
era using the Veterans Affairs Central Cancer Registry, 
and provide such information to Congress in follow-up re-
ports submitted under subsection (b)(2). 
(d) DEFINITIONS.—In this section: 
VerDate Sep 11 2014 
19:29 Feb 18, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H586.IH
H586
ssavage on LAPJG3WLY3PROD with BILLS
(1) The term ‘‘Vietnam era’’ has the meaning 
given such term in section 101 of title 38, United 
States Code. 
(2) The term ‘‘covered veterans of the Vietnam 
era’’ means veterans who served in the Vietnam the-
ater of operations during the Vietnam era. 
Æ 
VerDate Sep 11 2014 
19:29 Feb 18, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H586.IH
H586
ssavage on LAPJG3WLY3PROD with BILLS